Thank you for donating!

You can donate using the following services.

Need support today?

Main menu

News

  1. 14.02.22

    IB1001-301: Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study

    Read more

  2. 11.02.22

    Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States

    Read more

  3. 03.02.22

    Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C

    Read more

  4. 01.02.22

    Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO

    Read more

  5. 07.12.21

    Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

    Read more

2022 Niemann-Pick UK (NPUK). Registered Charity: England and Wales (1144406) / Scotland (SCO45407). Registered as a company limited by guarantee in England and Wales (07775835).

Donate today